LivaNova plc (LIVN) Tops Q3 EPS by 18c

LivaNova plc (NASDAQ: LIVN) reported Q3 EPS of $0.96, $0.18 better than the analyst estimate of $0.78. Revenue for the quarter came in at $309.7 million versus the consensus estimate of $300.48 million.

"We delivered solid sales and earnings performance in the third quarter, with record growth in several of our product areas," said Damien McDonald, LivaNova's Chief Executive Officer. “While we grew in Neuromodulation, results were impacted due to delays in procedures as a result of hurricane-related activity, and also from broad patient deferrals in anticipation of the launch of our newest VNS Therapy® System, SenTivaTM, which received U.S. Food and Drug Administration approval in early October. Growth in our Cardiac Rhythm Management business was slightly positive, aided by continued demand in Japan for our KORA250®device, even as we explore strategic options for this franchise. Cardiac Surgery had numerous positive initiatives that coalesced, resulting in mid-single-digit growth in both our cardiopulmonary and heart valve product lines. Due to our strong year-to-date results and momentum across our business, we are increasing our full-year guidance for adjusted diluted earnings per share to $3.30 to $3.45. We remain on track to meet our other full-year commitments and will continue to take actions that strengthen LivaNova’s position as a focused med-tech innovator dedicated to improving the lives of patients around the world."

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Atlassian (TEAM) comes ahead of Street estimates in Q1 but shares tumble
• NOV Inc (NOV) Tops Q1 EPS by 3c; offers guidance